Buscar
01/11/2023
Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study.
Rampotas A, Sockel K, Panitsas F, Theuser C, Bornhauser M, Hernani R, Hernandez-Boluda JC, Esquirol A, Avenoso D, Tsirigotis P, Robin M, Czerw T, Helbig G, Roddie C, Lambert J, McLornan DP. Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study.. Transplantation And Cellular Therapy. 2023; 29(11)DOI:10.1016/j.jtct.2023.08.020. PMID:37633414. IF:3.600(Q1/3D).
02/10/2023
Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
Baron F, Nagler A, Galimard JE, Sanz J, Versluis J, Forcade E, Chevallier P, Sirvent A, Anthias C, Kuball J, Furst S, Rambaldi A, Sierra J, von dem Borne PA, Gallego Hernanz MP, Cluzeau T, Robinson S, Raiola AM, Labussière-Wallet H, Byrne JL, Malfuson JV, Ruggeri A, Mohty M, Ciceri F. Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.. BRITISH JOURNAL OF HAEMATOLOGY. 2023; 204(1)DOI:10.1111/bjh.19130. PMID:37784256. IF:5.100(Q1/2D).
01/10/2023
Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.
Puertas B, González-Calle V, Sureda A, Moreno MJ, Oriol A, González E, Rosiñol L, López J, Escalante F, Martínez-Lopez J, Carrillo E, Clavero E, Ríos-Tamayo R, Rey-Bua B, González-Rodríguez AP, Dourdil V, De Arriba F, González S, Pérez-de-Oteyza J, Hernández MT, García-Mateo A, Bargay J, Bladé J, Lahuerta JJ, San Miguel JF, Ocio EM, Mateos MV. Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.. HAEMATOLOGICA. 2023; 108(10)DOI:10.3324/haematol.2022.282490. PMID:37102598. IF:10.100(Q1/2D).
26/09/2023
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.
Moreno C, Solman IG, Tam CS, Grigg A, Scarfò L, Kipps TJ, Srinivasan S, Mali RS, Zhou C, Dean JP, Szafer-Glusman E, Choi M. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.. Blood Advances. 2023; 7(18)DOI:10.1182/bloodadvances.2023010236. PMID:37315225. IF:7.400(Q1/2D).
23/05/2023
Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.
Rafii H, Ruggeri A, Kenzey C, Sanz J, Peffault de Latour R, Esquirol A, Michel G, Chevallier P, Rubio MT, Cornelissen JJ, Michallet M, Volt F, Rivera Franco MM, Scigliuolo GM, Cappelli B, Rocha V, Gluckman E. Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.. Blood Advances. 2023; 7(10)DOI:10.1182/bloodadvances.2022007941. PMID:36350759. IF:7.400(Q1/2D).
20/01/2026
Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024
Formigo, GMS, Mazorra, Z, Olexen, C, Menéndez, T, Hadi, LA, Handgretinger, R, Hernandez, AAB, El Najjar, I, Coukos, G, Sabzevari, H, Bollard, C, Couriel, D, Wald, D, Hamieh, M, Briones, J, Al Kaabi, F, Ventura-Carmenate, Y. Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024. Frontiers in Immunology. 2026; 16DOI:10.3389/fimmu.2025.1650023. PMID:41641269. IF:5.900(Q1/2D).